Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02437604 · ClinicalTrials.gov registry record · Phase 1
Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT02437604 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 43 participants.
The verdict
NCT02437604, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
Each patient will participate in the study for approximately 7 weeks. Participation will include a screening period of up to 21 days and 4 treatment periods; each consisting of a 3-day/2-night inpatient period.
Interventions
- DRUG Treatment A: Fp MDPI
- DRUG Treatment B: FS MDPI
- DRUG Treatment C Flovent
- DRUG Treatment D: Advair
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02437604
The ClinicalTrials.gov registry entry for NCT02437604 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Treatment A: Fp MDPI is the first listed.
NCT02437604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02437604 about?
NCT02437604 is a clinical study titled "Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older". Each patient will participate in the study for approximately 7 weeks. Participation will include a screening period of up to 21 days and 4 treatment periods; each consisting of a 3-day/2-night inpatient period.
What is the current status of trial NCT02437604?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2015-05. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02437604?
The interventions under investigation include: Treatment A: Fp MDPI (DRUG), Treatment B: FS MDPI (DRUG), Treatment C Flovent (DRUG), Treatment D: Advair (DRUG).
Who is sponsoring clinical trial NCT02437604?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.